When one in eight American adults—over 30 million people—report taking GLP-1 medications such as Ozempic in 2024, according to the Kaiser Family Foundation, investors across food, supplement, and healthcare sectors are taking notice. This isn’t merely a fleeting weight-loss trend; it signifies a fundamental shift, creating new market categories and unprecedented investment opportunities. Originally developed for Type 2 diabetes management, Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly transcended their initial therapeutic niche, evolving into a transformative force impacting consumer behavior, dietary habits, and the global economy. This evolution, accelerated by widespread adoption and celebrity endorsements, is prompting a reevaluation of nutritional science and driving innovation across various industries.
The Dawn of the "Economy of Transformation"
The profound impact of widespread GLP-1 usage has been termed the "Economy of Transformation" by Brian Sugar, co-founder and managing partner of Sugar Capital, a San Francisco venture capital firm. Sugar, who personally experienced a 40-pound weight loss on Ozempic, believes he has identified the core opportunity within this burgeoning market. "Nobody needs to compete with Ozempic. They need to accessorize it," Sugar asserts. He dismisses numerous pitches for products like berberine, metabolic teas, and Akkermansia probiotics, which are often marketed as "nature’s Ozempic," arguing they miss the fundamental point of the GLP-1 phenomenon.
Sugar highlights that the physiological changes induced by GLP-1 medications are not transient side effects but rather permanent conditions of transformation. These can include muscle loss, protein malabsorption, magnesium depletion, and hair thinning. "These aren’t problems to solve so you can return to normal," he explains. "Normal is gone. These are the permanent conditions of transformation." This perspective underscores the shift from viewing GLP-1s as a temporary weight-loss solution to recognizing them as catalysts for lasting physiological and lifestyle alterations, thereby creating a sustained demand for supporting products and services.
Sugar Capital’s investment strategy exemplifies this approach. The firm participated in Grüns’ $1.8 million pre-seed round in 2023 and its subsequent $35 million Series B round. Grüns, a celebrity-backed brand, offers gummies formulated with 60 ingredients, including whole foods, adaptogens, and prebiotics, specifically designed to fill critical nutrient gaps. "Grüns was solving a problem most investors couldn’t see," Sugar states. "Bodies consuming 40% fewer calories still need complete nutrition. They aren’t selling to people on diets. They’re selling to people in different bodies." This highlights a nuanced understanding of the GLP-1 user’s evolving nutritional needs.
Emerging Investment Categories Driven by GLP-1s
The venture capital market is responding proactively to the growing GLP-1 user base, with significant funding flowing into services that connect individuals with registered dietitians and nutritionists. This trend reflects a growing understanding that pharmacological interventions like GLP-1s require comprehensive nutritional and lifestyle support for optimal outcomes and long-term health management.
Nutrition Support Platforms: The Insurance-Backed Solution
Berry Street, a platform offering "nutrition therapy, covered by insurance," secured $50 million earlier this year from investors including Northzone, Sofina, and FJ Labs. Similarly, Fay Nutrition, an AI-powered "preventative care platform" that pairs users with licensed nutrition professionals, announced in October a $50 million Series B funding round from investors such as Goldman Sachs, General Catalyst, and Forerunner Ventures. These substantial investments underscore the perceived value and scalability of integrated nutrition support services in the GLP-1 era.
Noah Kotlove, CEO of Berry Street, co-founded the company in 2023 after a nutritionist helped him achieve a 65-pound weight loss. He observed that while most insurance companies cover nutrition consultations, awareness and utilization among the public remained low. The Berry Street platform streamlines this connection and payment process. "Insurance companies are happy to pay for [nutrition consultations] because it’s preventing more costly treatment," Kotlove explains. "GLP-1s have hastened this prioritization as they’re becoming such an unwieldy cost for insurers." This perspective highlights the economic rationale behind the increased adoption of preventative and supportive health services, driven in part by the escalating costs associated with obesity and related comorbidities, which GLP-1s are helping to manage.
Michele Rager, Berry Street’s head of clinical nutrition, reports that over 20% of their platform patients are currently taking GLP-1s and actively engaging with registered dietitians daily. Rager has witnessed the rapid ascent of GLP-1s from their initial use in Type 2 diabetes management to their popularization for weight loss by celebrities such as Chrissy Teigen, Kelly Clarkson, and Kathy Bates, and their subsequent widespread prescription for weight management. "GLP-1s are now something I hear and talk about from a higher leadership level every day," she notes.
Rager cautions against viewing GLP-1s as a "magic bullet," emphasizing their efficacy when integrated with lifestyle and behavioral changes, including dietary adjustments and supplementation. While some nutritional supplements may offer minor benefits, she stresses that the most significant impact, beyond prescribed medications, comes from adopting healthy lifestyle factors. "The lion’s share of impact you can make, other than with these prescribed medications, is with lifestyle and diet, making sure you’re eating the right things, moving properly and supporting all these healthy lifestyle factors," Rager advises. This holistic approach aligns with the growing consensus that sustainable health outcomes require a multi-faceted strategy.
The Healthier Food Push: "Food as Medicine" Gains Traction
Marcia Hooper, a partner at Branch Venture Group, an angel investment network focused on food and beverage CPG, foodtech, and agtech ventures, acknowledges that the group has not yet invested in GLP-1-specific companies. However, they are closely monitoring the space due to the potential for GLP-1s to accelerate the "food as medicine" (FAM) movement, a key socially responsible focus area for the group. FAM programs, which include medically tailored meals and produce prescriptions, provide nutrient-dense foods to individuals facing chronic illness or food insecurity. While historically driven by charitable organizations and publicly funded health insurance programs, some private insurers are now piloting FAM programs for eligible patients.
For individuals using GLP-1 drugs for weight reduction, success is often accompanied by significant loss of muscle mass and bone density. Hooper notes, "Since most people feel like eating less, what they consume needs to be nutrient dense to keep muscle tissue vibrant." This physiological reality creates a demand for nutrient-rich foods and specialized dietary approaches.
Big food companies are keenly observing the GLP-1 trend, according to Larissa Zimberoff, author of Technically Food: Inside Silicon Valley’s Mission to Change What We Eat. She links GLP-1s to a growing consumer sentiment against ultra-processed foods (UPFs). "Consumers on GLP-1s are buying less junk food but still snacking. They’re looking for healthier options," Zimberoff observes. "Because they’re eating far less, getting the right nutrients in the right amounts becomes critical." This shift in consumer priorities is compelling food manufacturers to innovate and reformulate products to meet the demand for healthier, more nutrient-dense alternatives.
Both Hooper and Zimberoff point to several ways corporate food companies are responding to the GLP-1 trend:
- Reformulation of existing products: Companies are re-evaluating ingredient lists to reduce sugar, unhealthy fats, and artificial additives while increasing protein and fiber content in snacks and meals.
- Development of new product lines: The emergence of specialized foods designed to be calorie-dense and nutrient-rich is anticipated, catering specifically to the reduced appetite and heightened nutritional needs of GLP-1 users.
- Strategic partnerships and acquisitions: Larger food corporations may seek to acquire or partner with innovative food tech startups that are developing solutions for the GLP-1 market.
- Increased focus on whole foods and minimally processed ingredients: The trend towards healthier eating, amplified by the GLP-1 effect, is driving demand for products that emphasize natural, unprocessed ingredients.
Specialized Supplement Development: Addressing the Gaps
Beyond the broader food industry, there is a significant opportunity for vitamin and supplement makers, according to Zimberoff. She cites GNC’s dedicated GLP-1 supplement section as an example, featuring products designed to support the body’s GLP-1 production, enhance metabolic health, improve gut microbiome function for better nutrient absorption, provide high-protein formulations with minimal volume, and support muscle growth.
To address the digestive changes often associated with GLP-1 use, many companies are focusing on fiber and prebiotic products. Zimberoff also identifies inflammation as another area poised for growth within the GLP-1 consumer segment. The development of targeted supplements addressing specific side effects and nutritional deficiencies is becoming a critical growth area for the supplement industry, moving beyond general wellness to highly specialized formulations.
Foodtech Innovation Pipeline: Concentrated Nutrition for Evolving Needs
The growing demand for better-for-you products, spurred by the GLP-1 market and broader consumer trends, is prompting ingredient companies to innovate. Mista, a San Francisco-based food laboratory with investors like Givaudan and Ingredion, exemplifies this forward-looking approach. Scott May, co-founder and chief innovation officer at Mista, explains their role: "We identify and curate early-stage companies that are bringing unique, interesting technologies to the forefront and disrupting many parts of the food system. We help connect these start-ups to big companies, so they can begin to incorporate them into portfolios." The overarching objective is to leverage new ingredient technologies in conjunction with existing solutions.
At Mista’s Healthy Nutrition Symposium in March, representatives from 60 companies convened to address challenges posed by the GLP-1 and UPF trends. One working group focused on creating a product for GLP-1 users experiencing reduced appetite but struggling to meet protein and nutrient intake requirements. The resulting prototype was a 125-milliliter beverage containing 21 grams of protein and 5 grams of fiber, fortified with encapsulated vitamins A, D, and E to provide 100% of the daily value, all without the characteristic "vitamin taste." This concentrated nutrition solution, designed in a format similar to energy shots found in convenience stores, represents the kind of innovation the GLP-1 market is demanding—highly efficient, nutrient-dense options for individuals with altered caloric intake.
Investment Implications: A Paradigm Shift in Health and Wellness
Marcia Hooper offers a compelling analogy for the role of GLP-1s: "I think of GLP-1s like eyeglasses for the gut. If you’re nearsighted or farsighted, corrective lenses really help you. And if your gut doesn’t digest food at a speed that can work with your metabolism, a GLP-1 can be really helpful." This perspective underscores that GLP-1s are increasingly being viewed not as a temporary diet fix but as a permanent health management tool, analogous to other assistive medical devices.
This permanence translates into sustainable market opportunities for investors who can look beyond traditional weight-loss categories. The GLP-1 trend presents three distinct investment horizons:
- Immediate Opportunities: These include nutritional support services, particularly those with established insurance reimbursement models, such as Berry Street and Fay Nutrition. The integration of these services into mainstream healthcare is accelerating due to their proven ability to support patients undergoing significant metabolic changes.
- Medium-Term Opportunities: This category encompasses the development of specialized supplements and functional foods designed to address the specific side effects and nutritional gaps experienced by GLP-1 users. This includes products focused on muscle preservation, nutrient absorption, and gut health.
- Longer-Term Opportunities: These involve pioneering food technology innovations that create nutrient-dense, minimal-volume food and beverage products. The demand for highly concentrated, palatable, and effective nutritional solutions will likely drive innovation in food science and manufacturing.
The supplement industry, in particular, stands to benefit from a fundamental shift in its market focus. The emphasis is moving from selling products to individuals seeking to lose weight to serving a population living with permanently transformed metabolisms. This necessitates a strategic pivot towards products that support sustained metabolic health, muscle maintenance, and overall well-being in individuals who have undergone significant physiological changes. As the GLP-1 revolution continues to unfold, companies and investors that adapt to this evolving landscape will be best positioned to capitalize on its transformative potential.
